Abstract
In western countries, hepatitis C virus (HCV)-related end-stage cirrhosis represents the most frequent indication for liver transplantation (LT) (www.unos.org, www.eltr.org). Reinfection occurs invariably in those who are viremic at transplantation resulting in recurrent disease with uncertain outcome. Several factors, in particular, donor age, have shown to influence the natural history of HCV post-transplantation. Understanding which factors determine disease and patient outcomes, which modifications can be implemented to improve results, the feasibility of use and diagnostic reliability of available tools for monitoring disease evolution, and the place of retransplantation (RT) are still essential aspects in the setting of limited access to new antiviral drugs as well as for those failing new antiviral regimes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hill AM, Saleem J, Heath KA, et al. Effects of Sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. American Association for the Study of Liver Diseases (AASLD) liver meeting, Boston, Oct 2014, abstract 44; Hepatology. 2014;60(S1):219A.
Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt1):329–37.
Van der Meer AJ, Heathcote EJ, Janssen HLA. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.
García-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–7.
Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28–34.
Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.
Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl. 2003;9(11):1152–8.
Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–6.
Bacchetti P, Boylan RD, Terrault N, et al. Non-Markov multistate modelling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplantation. Int J Biostat. 2010;6(1):Article 7.
Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1–9.
Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16(11):1228–35.
Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78–88.
Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology. 2000;32:852–8.
Forman LM, Lewis J, Berlin J, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–96.
Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection. Am J Transplant. 2008;8:404.
Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250–6.
Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut. 2002;50(5):697–700.
Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 2004;10:1240–7.
Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88(10):1214–21.
Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl. 2009;15(7):738–46.
Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14(12):1766–77.
Blasco A, Forns X, Carrión JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43(3):492–9.
Carrión JA, Torres F, Crespo G, et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology. 2010;51(1):23–34.
Manousou P, Burroughs AK, Tsochatzis E, et al. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol. 2013;58:962–8.
Manousou P, Cholongitas E, Samonakis D, et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. 2014;63(6):1005–13.
Calvaruso V, Dhillon AP, Tsochatzis E, et al. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol. 2012;27(7):1227–32.
Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol. 2006;45:127–43.
Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol. 2005;42(4):448–56.
Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 2003;9:S63–6.
Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6(8):1922–9.
Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patient co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407–17.
Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36:202–10.
Feng S, Goodrivh NP, Btagg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783–90.
Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl. 2008;14 Suppl 2:S45–50.
Lai JC, O’Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012;18:532–8.
Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–44.
Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53:317–24.
Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55:322–7.
Shackel NA, Jamias J, Rahman W, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C related liver failure post-liver transplantation. Liver Transpl. 2009;15(7):709–18.
Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36–44.
Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology. 1995;108(4):1088–96.
Feray C, Caccamo L, Alexander GJM, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology. 1999;117(3):619–25.
Pageaux GP, Ducos J, Mondain AM, et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transpl Surg. 1997;3(5):501–5.
Taner CB, Bulatao IG, Keaveny AP, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl. 2011;17:641–9.
Zekry A, Whiting P, Crawford DH, et al. Liver transplant for HCV-associated liver cirrhosis: recipient predictors of outcomes in population with significant genotypes 3 and 4 distribution. Liver Transpl. 2003;9:339–47.
Wali MH, Heydtmann M, Harrison RF, et al. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl. 2003;9:796–804.
Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007;13(1):122–9.
Terrault NA, Stravitz RT, Lok AS, et al. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology. 2014;59(4):1311–9.
Tao R, Ruppert K, Cruz Jr RJ, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl. 2010;16(11):1288–95.
Uemura T, Ramprasad V, Hollenbeak CS, et al. Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2012;12(4):984–91.
Wells M, Croome KM, Janik T, et al. Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2014;28(2):103–8.
Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 2007;13:733–40.
Lai JC, Verna EC, Brown RS, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54:418–24.
Lai JC, Feng S, Roberts JP, et al. Gender differences in liver donor quality are predictive of graft loss. Am J Transplant. 2011;11(2):296–302.
Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008;14(9):1287–93.
Brandman D, Pingitore A, Lai JC, et al. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl. 2011;17:1380–6.
Veldt BJ, Poterucha JJ, Watt KD, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009;9:1406–13.
Saxena V, Lai JC, O’Leary JG, et al. Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl. 2012;18:524–53.
Layden JE, Cotler SJ, Grim SA, et al. Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation. 2012;93:444–9.
Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716–26.
Moreno S, Fortun J, Quesada C, et al. Liver Transplantation in HIV-infected recipients. Liver Transpl. 2005;11:76–81.
Borentain P, Colson P, Dhiver C, et al. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient. Antivir Ther. 2015;20(3):353–6. doi:10.3851/IMP2841.
Humar A, Washburn K, Freeman R, et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl. 2007;13(10):1422–7.
Tong CY, Bakran A, Williams H, et al. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol. 2001;64:29–34.
Bosch W, Heckman MG, Pungpapong S, et al. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation. 2012;93(7):723–8.
Gedaly R, Clifford TM, McHugh PP, et al. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int. 2008;21:867–72.
Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006;44:717–22.
Rubín A, Berenguer M. Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma. Gastroenterol Hepatol. 2013;36(1):48–57.
Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012;56(4):973–83.
Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11:384–5.
O’Leary JG, Trotter JF, Neri MA, et al. Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Baylor Univ Med Cent). 2011;24:187–91.
Irish W, Arcona S, Bowers D, et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant. 2011;11(8):1676–85.
Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10:1258–62.
Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2 T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006;12:1464–72.
Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl. 2006;12:762–7.
Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus positive recipients. Transplantation. 2010;90:1204–9.
Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a metaanalysis. Liver Transpl. 2007;13:21–9.
Duvoux C, Firpi R, Grazi GL, et al. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. Transpl Int. 2013;26(4):358–72.
Garcia-Saenz-de-Sicilia M, Mukherjee S. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice. Expert Rev Clin Pharmacol. 2012;5(5):587–93.
Yoshida EM, Lilly LB, Marotta PJ, et al. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Ann Hepatol. 2013;12(2):282–93.
Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226–31.
Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–20.
Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 1998;28:756–63.
Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011;17:1394–403.
Takada Y, Kaido T, Asonuma K, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl. 2013;19:896–906.
Llado L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl. 2008;14:1752–60.
Zekry A, Gleeson M, Guney S, et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004;10:52–7.
Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of Mycophenolate Mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 2002;8:40–6.
Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant. 2009;9:1725–31.
Patsenker E, Schneider V, Ledermann M, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011;55:388–98.
Watt KD, Dierkhising R, Heimbach JK, et al. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012;18:1029–36.
Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640–8.
De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008–20.
Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001;7:1064–70.
Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002;8:123–31.
Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002;8:132–42.
Moonka DK, Kim D, Kapke A, et al. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant. 2010;10(3):590–601.
McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage following liver transplantation. J Hepatol. 2004;40:368–74.
Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology. 1999;29(2):365–70.
Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology. 2003;38:460–9.
Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl. 2003;9:1019–24.
Northup PG, Pruett TL, Kashmer DM, et al. Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. Am J Transpl. 2007;7:1984–8.
Markmann JF, Gornbein J, Markowitz JS, et al. A simple model to estimate survival after retransplantation of the liver. Transplantation. 1999;67:422–30.
Andres A, Gerstel E, Combescure C, et al. A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation. 2012;93(7):717–22.
Pfitzmann R, Benscheidt B, Langrehr JM, et al. Trends and experiences in liver retransplantation over 15 years. Liver Transpl. 2007;13:248–57.
Kashyap R, Jain A, Reyes J, et al. Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2-19 years follow-up. Transplant Proc. 2001;33:1486–7.
Biggins SW, Terrault NA. Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl. 2003;9:236–8.
Carrión JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence alter liver transplantation. J Hepatol. 2010;53:962–70.
Biggins SW, Gralla J, Dodge JL, et al. Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. Am J Transplant. 2014;14(11):2588–94.
Briceño J, Cruz-Ramírez M, Prieto M, et al. Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: results from a multicenter Spanish study. J Hepatol. 2014;61(5):1020–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rubín, A., Berenguer, M. (2016). HCV Recurrence: Predictors and Outcomes After Liver Transplantation. In: Thuluvath, P. (eds) Disease Recurrence After Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2947-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2947-4_3
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2946-7
Online ISBN: 978-1-4939-2947-4
eBook Packages: MedicineMedicine (R0)